In this conversation, Anne and Karina discuss the integration of AI in Quality Assurance (QA) and the lessons learned from data integrity requirements. They explore the regulatory landscape surrounding AI, its applications in drug discovery and clinical trials, and the importance of training and vendor qualification. The conversation highlights the potential risks associated with AI usage and emphasizes the need for proactive measures in organizations to ensure data integrity and compliance.
To learn more check out Karina's article on LinkedIn: https://www.linkedin.com/posts/activity-7284932351883632641-fOQ6?utm_source=social_share_send&utm_medium=member_desktop_web&rcm=ACoAAATG5rsBXUVcnuzQQOb1xrZJBHv_wShKhe0
